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Monocyte/ chemoattractant protein-1/chemokine li-
gand (CCL) 2 and stromal cell–derived factor-1/
CXCL12 both contribute to glomerulosclerosis in mice
with type 2 diabetes mellitus, through different mech-
anisms. CCL2 mediates macrophage-related inflam-
mation, whereas CXCL12 contributes to podocyte
loss. Therefore, we hypothesized that dual antago-
nism of these chemokines might have additive pro-
tective effects on the progression of diabetic nephrop-
athy. We used chemokine antagonists based on
structured L-enantiomeric RNA (so-called Spiegel-
mers) ie, the CCL2-specific mNOX-E36 and the
CXCL12-specific NOX-A12. Male db/db mice, unine-
phrectomized at the age of 6 weeks, received injec-
tions of Spiegelmer, both Spiegelmers, nonfunctional
control Spiegelmer, or vehicle from the age of 4
months for 8 weeks. Dual blockade was significantly
more effective than monotherapy in preventing glo-
merulosclerosis. CCL2 blockade reduced glomerular
leukocyte counts and renal-inducible nitric oxide syn-
thase or IL-6 mRNA expression. CXCL12 blockade
maintained podocyte numbers and renal nephrin and
podocin mRNA expression. Consistently, CXCL12
blockade suppressed nephrin mRNA up-regulation in
primary cultures of human glomerular progenitors
induced to differentiate toward the podocyte lineage.
All previously mentioned parameters were signifi-
cantly improved in the dual-blockade group, which
116also suppressed proteinuria and was associated with
the highest levels of glomerular filtration rate. Blood
glucose levels and body weight were identical in all
treatment groups. Dual chemokine blockade can have
additive effects on the progression of diabetic kidney
disease when the respective chemokine targets medi-
ate different pathomechanisms of disease (ie, inflam-
mation and progenitor differentiation toward the
podocyte lineage). (Am J Pathol 2011, 179:116–124; DOI:
10.1016/j.ajpath.2011.03.004)
Diabetic nephropathy (DN) is a leading cause of chronic
kidney disease.1–3 Novel treatment strategies are neces-
sary because the current concept of angiotensin block-
ade and blood pressure control cannot prevent disease
progression in all cases.4 In DN, the glomerular tuft un-
dergoes a slow but progressive structural remodeling
characterized by glomerular hypertrophy, diffuse and
nodular accumulation of extracellular mesangial matrix,
and podocyte damage.5 The latter is thought to account
for the progression of microalbuminuria from early stages
to overt proteinuria and glomerulosclerosis at late-stage
DN. The onset and progression of DN involves numerous
additional pathomechanisms, including the deposition of
advanced glycation end products, endothelial dysfunc-
tion, and increased local expression of growth factors
and proinflammatory mediators.6 Most chemokines be-
long to the latter group of factors because proinflamma-
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eling by recruiting and activating immune cells in DN, as
in other types of kidney diseases.7–10 For example, tar-
geted deletion or inhibition of monocyte chemoattractant
protein-1 [renamed chemokine ligand (CCL) 2] signaling
can prevent glomerulosclerosis by blocking macrophage
recruitment to the glomeruli of mice with type 1 or 2
diabetes mellitus.11,12 In fact, CCL2 may represent a
promising therapeutic target in DN because delayed on-
set of CCL2 blockade was able to prevent diabetic glo-
merulosclerosis and restore the glomerular filtration rate
(GFR) by preventing glomerular macrophage recruitment
in late-stage DN of uninephrectomized db/db mice with
type 2 diabetes.13
Although structurally related, a subgroup of the
chemokine superfamily, known as “homeostatic” chemo-
kines, displays functions independent of tissue inflamma-
tion. Homeostatic chemokines are rather constitutively
expressed because they contribute to the physiological
homing and migration of immune cells in the bone mar-
row or lymphoid organs.14 For example, recently, the
homeostatic chemokine stromal cell–derived factor-1,
also named CXCL12, was constitutively expressed by
podocytes and CXCL12 blockade prevents diabetic glo-
merulosclerosis in a way that was independent of glomer-
ular macrophage recruitment.15 The mechanism under-
lying the protective effect of CXCL12 blockade on DN
remains unclear, but a profound effect on podocyte
counts and proteinuria was documented. Because we
could not detect increased bone marrow–derived pro-
genitor cells in kidneys of treated db/db mice, an en-
hancer effect on the capacity of intraglomerular podocyte
progenitors to restore podocytes in DN was suspected.15
Our previous attempts to increase the therapeutic
effects of chemokine blockade on the progression of
DN were not successful. For example, blockade of
CCR2 and CCR5 with a dual antagonist did not reveal
any additional effects compared with single CCR
blockade (S.G.S and H.J.A., unpublished data). We
had attributed this finding to the fact that CCR2 and
CCR5 are redundant when coexpressed on the same
class of monocytes, which may preclude additive ef-
fects on glomerular pathological characteristics in DN.
Therefore, we hypothesized that combining the protec-
tive effects of reducing glomerular leukocyte recruitment
by blocking the proinflammatory chemokine CCL2 with
the protective effects on podocyte loss by blocking the
homeostatic chemokine CXCL12 should finally elicit ad-
ditive protective effects on diabetic glomerulosclerosis.
As such, we compared monotherapy of either CCL2 or
CXCL12 antagonists with dual blockade in an acceler-
ated model of glomerulosclerosis in db/db mice with type
2 diabetes.
Materials and Methods
CCL2 and CXCL12 Antagonistic Spiegelmers
The sequences of the CCL2 antagonistic Spiegelmer
mNOX-E36 (5=-GGCGACAUUGGUUGGGCAUGAGGC-GAGGCCCUUUGAUGAAUCCGCGGCCA-3=) and the
CXCL12 antagonistic Spiegelmer NOX-A12 (5=-GCGUG-
GUGUGAUCUAGAUGUAUUGGCUGAUCCUAGUCAG-
GUACGC-3=) were obtained from in vitro selection exper-
iments that were essentially performed as described.16
To distinguish possible target-specific from unspecific
substance class effects, a nonfunctional Spiegelmer with
the reverse sequence of NOX-A12 (5=-CGCAUGG-
ACUGAUCCUAGUCGGUUAUUAGAUCUAGUGUGGU-
GCG-3=) was used. The Spiegelmers were modified with
40-kDaba branched polyethylene glycol at the 3= end
(mNOX-E36) or the 5= end (NOX-A12 and reverse
sequence of NOX-A12). mNOX-E36 and NOX-A12 bind
to CCL2 and CXCL12, respectively, with subnanomolar af-
finities. Chemokine inhibition was determined for each
Spiegelmer using leukocyte chemotaxis assays, as de-
scribed.16,17 All Spiegelmers were previously tested as sin-
gle agents in DN by our group, as described.13
Animal Studies
Male diabetic C57BLKS db/db mice or nondiabetic
C57BL/6 mice, aged 5 weeks, were obtained from Tac-
onic (Ry, Denmark) and housed in filter-top cages with a
12-hour dark-light cycle. All animals had unlimited ac-
cess to food and water throughout the duration of the
study. At the age of 6 weeks, uninephrectomy (1K mice)
or sham surgery was performed through a 1-cm flank
incision, as previously described.18 In the sham surgery
group, the kidney was left in situ. At the age of 4 months,
1K db/db mice with documented blood glucose levels
11 mmol/L and creatinine/albumin ratios 3 (ratio in
age-matched wild-type mice, 0.1) were divided into four
groups (n  10 to 12); each of these groups received
either nil (no injections) or s.c. injections of 50 mg/kg
NOX-A12, mNOX-E36, or control Spiegelmer in 5% glu-
cose or 5% glucose itself as a vehicle control, on every
other day. This dose corresponds to 13.4 mg/kg NOX-
A12 or 14.4 mg/kg mNOX-A36 if based on the oligonu-
cleotide part of the molecule as anhydrous free acid.
The treatment dose and injection intervals were com-
parable to those in previous db/db mouse stud-
ies,13,15,19 with similar formulations of Spiegelmers tar-
geting these chemokines. Treatment was continued for
8 weeks. Tissues were harvested for histopathological
evaluation at the end of the treatment period, 3 to 4
hours after the last Spiegelmer injection. Blood and
urine samples were obtained at monthly intervals for
the estimations of urinary albumin, by enzyme-linked
immunosorbent assay (Bethyl Labs, Montgomery, TX);
and serum and urinary creatinine, by Jaffé reaction
(DiaSys Diagnostic Systems, Holzheim, Germany).
Blood glucose levels were monitored using an Accu
check sensor (Roche, Mannheim, Germany). Plasma
chemokine levels were determined at the end of the
treatment period by enzyme-linked immunosorbent as-
say (CCL2: BD Biosciences Pharmingen, San Diego,
CA; CXCL12: R&D Systems, Wiesbaden, Germany). All
animal experiments were approved by the local gov-
ernment authorities.
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Kidneys were harvested from eachmouse and were fixed in
10% formalin in PBS and embedded in paraffin. Sections, 2
m, were stained with PAS reagent. Glomerular sclerotic
lesions were assessed using a semiquantitative score by a
blinded observer, as follows: 0 indicates no lesion; 1,25%
sclerotic; 2, 25% to 49% sclerotic; 3, 50% to 74% sclerotic;
and 4, 75% to 100% sclerotic. Fifteen glomeruli were ana-
lyzed per section. The number of glomerular cells was de-
termined on PAS stains by counting cell nuclei in 15 glo-
merular tufts per section. Pole-cutted glomerular cross
sections were ignored. Immunostaining was performed, as
described,20 using the following primary antibodies: CD45
(leukocytes; BD Biosciences, Mannheim; 1:10), Wilms tu-
mor (WT)1 (podocytes; Santa Cruz, Santa Cruz, CA;
1:200), Ki-67 (proliferating cells; Dianova, Hamburg, Ger-
many; 1:50), terminal deoxynucleotidyl transferase-medi-
ated dUTP nick-end labeling (TUNEL; apoptotic cells;
Roche, Mannheim; 1:10). TUNEL- and DAPI-positive cells
(Sigma-Aldrich, Steinheim, Germany) were counted by flu-
orescent microscopy, and all other stains were assessed by
light microscopy in 15 glomeruli per section by a blinded
observer (H.J.M.).
In Vitro Studies
Normal renal tissues were obtained from four patients who
underwent nephrectomy because of renal cell carcinoma,
in agreement with the Ethical Committee on Human Exper-
imentation of the Azienda Ospedaliero–Universitaria Car-
eggi, Florence, Italy. Human embryonic kidney 293 cells
were purchased from American Type Culture Collection
(Manassas, VA) and cultured as specified by the supplier.
The human keratinocyte cell line was a gift from Dr. Rosa
Mancina (Florence, Italy). Human renal progenitors were
obtained by immunomagnetic sorting for CD133 after de-
pletion of digested total renal cell suspensions for CD45
and podocalyxin, as previously described.18 Primary cul-
tures of human renal progenitors were 99% positive for
CD133 and CD24 coexpression, as checked by fluores-
cence-activated cell sorter analysis. Podocyte markers
were absent. For podocyte differentiation, cells were treated
for 2 days with VRADmedium, as previously described.18,21
Nephrin mRNA quantification was performed using Assay
on Demand kits (Applied Biosystems, Warrington, UK),20,21
according to the manufacturer’s recommendations; and
Taq-Man RT-PCR was performed using a 7900HT Real
Time PCR System (Applied Biosystems), as previously de-
scribed.20,21 To accurately compare samples by real-time
RT-PCR, an identical number of cells (n  10,000) was
analyzed in all experiments; and glyceraldehyde-3-pho-
shate dehydrogenase was used to evaluate mRNA quality
and integrity.
RNA Preparation and Real-Time Quantitative
(TaqMan) RT-PCR
Total RNA was isolated from kidneys using a Qiagen
RNA extraction kit (Hilden, Germany) following the
manufacturer’s instructions. After quantification, RNAquality was assessed using agarose gels. From iso-
lated RNA, cDNA was prepared using reverse trans-
criptase (Superscript II; Invitrogen, Carlsbad, CA).
Real-time PCR was performed using SYBR Green PCR
master mix, and results were analyzed with a Light
Cycler 480 (Roche). All gene expression values were
normalized using 18s RNA as a housekeeping gene. All
primers used for amplification were from Metabion (Martin-
sried, Germany): CCL2 (sense, 5=-CCTGCTGTTCACAGT-
TGCC-3=; antisense, 5=-ATTGGGATCATCTTGCTGGT-3=),
CXCL12 (sense, 5=-TTTCAGATGCTTGACGTTGG-3=; anti-
sense, 5=-GCGCTCTGCATCAGTGAC-3=), tumor necrosis
factor (sense, 5=-AGGGTCTGGGCCATAGAACT-3=; anti-
sense, 5=-CCACCACGCTCTTCTGTCTAC-3=), inducible ni-
tric oxide synthase (sense, 5=-TGAAGAAAACCCCTTGT-
GCT-3=; antisense, 5=-TTCTGTGCTGTCCCAGTGAG-3=),
nephrin (sense, 5=-CTCTTTCTACCGCCTCAACG-3=; anti-
sense, 5=-TTAGCAGACACGGACACAGG-3=), podocin
(sense, 5=-CAGGAAGCAGATGTCCCAGT-3=; antisense,
5=-TGACGTTCCCTTTTTCCATC-3=), IL-6 (sense, 5=-ACCA-
GAGGAAATTTTCAATAGGC-3=; antisense, 5=-TGATGCA-




Data are presented as mean  SEM. A comparison of
groups was performed using an analysis of variance, and
post hoc Bonferroni’s correction was used for multiple
comparisons. P  0.05 indicated statistical significance.
Results
Dual CCL2-CXCL12 Blockade Has Additive
Effects on Glomerulosclerosis in db/db Mice
To test our hypothesis, we initiated s.c. injections with
vehicle alone, control Spiegelmer, mNOX-E36 (anti-CCL2
Spiegelmer), NOX-A12 (anti-CXCL12 Spiegelmer), or a
combination of the latter two at a dose of 50 mg/kg given
every other day from the age of 4 to 6 months in unine-
phrectomized db/db mice. To ensure Spiegelmer expo-
sure and its biological activity in vivo, we determined
plasma CCL2 and CXCL12 levels at the beginning and
the end of the study. Plasma CCL2 and CXCL12 levels
remained undetectable or low in sham–operated on
db/db mice and vehicle- or control Spiegelmer–treated
1K db/db mice. Anti-CXCL12 or anti-CCL2 Spiegelmer
injections increased the plasma levels of either chemo-
kine in 1K db/db mice (Figure 1). This finding is consis-
tent with previous observations13,15,17 with these Spiegel-
mers, indicating that Spiegelmer antagonists retain their
molecular targets in the circulation. Such Spiegelmer-
chemokine complexes no longer display chemotactic ac-
tivity in trans-well migration assays (data not shown).
Body weight and blood glucose levels did not differ
among the injected 1K db/db mice groups (Figure 2).
Renal histomorphological features in 6-month-old db/db
mice showed moderate glomerulosclerosis compared
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sham surgery, which was aggravated to diffuse glomer-
ulosclerosis by early uninephrectomy of db/db mice (Fig-
ure 3). CCL2 and CXCL12 inhibition reduced the extent of
glomerulosclerosis in uninephrectomized db/db mice to
the level of age-matched sham–operated on db/db mice,
whereas the control Spiegelmer had no effect. Dual
CCL2-CXCL12 blockade further improved glomerular
pathological features, with significantly less severe le-
sions and more normal glomeruli compared with either of
the monotherapies. 1K db/db mice with dual blockade
displayed even less glomerular pathological features
than age-matched db/db mice that underwent sham sur-
gery (Figure 3B). Thus, dual CCL2-CXCL12 blockade has
additive protective effects on glomerulosclerosis in 1K
db/db mice.
Only CCL2 Blockade Reduces Leukocyte
Numbers in Glomeruli of 1K db/db Mice
Chemokine-mediated glomerular pathological features in
db/db mice can be mediated by leukocyte recruit-
ment.11,13 Therefore, we evaluated the number of glomer-
ular leukocytes by immunostaining for CD45. Significant
numbers of CD45 leukocytes were detected in glomer-
uli of vehicle- or control Spiegelmer–treated 1K db/db
mice (Figure 4). Consistent with previous data,13,15 the
numbers of glomerular CD45 leukocytes were signifi-
cantly reduced by CCL2, but not by CXCL12, blockade.
The numbers of glomerular leukocytes were also reduced
accordingly with dual-chemokine blockade (Figure 4).
Therefore, blockade of the proinflammatory chemokine
CCL2, but not of the homeostatic chemokine CXCLl2,
affects the number of glomerular leukocytes in db/db
Figure 1. Plasma chemokine levels in Spiegelmer-treated db/db mice.
Plasma CCL2 and CXCL12 levels were determined in 14- and 24-week-old
uninephrectomized db/db mice by enzyme-linked immunosorbent assay,
which represents before and after treatment. Data are given as mean  SEM.
*P  0.001 versus the 24-week vehicle group.mice.Dual CCL2-CXCL12 Blockade Has Additive
Effects on Podocyte Numbers in db/db Mice
Previously, CXCL12 blockade protected 1K db/db mice
from podocyte loss as another marker of glomerular path-
ological features in db/db mice.15 We questioned
whether dual-chemokine blockade would have additive
protective effects on podocytes and quantified glomeru-
lar podocytes by WT-1 immunostaining in all groups of 1K
db/db mice. Compared with an average number of 15 to
20 WT-1–positive podocytes in murine glomerular cross
sections (data not shown), the 6-month-old 1K db/db
mice revealed only an average of 11 cells per glomerular
cross section. CCL2 and, particularly, CXCL12 blockade
both significantly increased glomerular podocyte counts
(Figure 5). Interestingly, dual CCL2-CXCL12 blockade
showed a small, but statistically significant, additive ef-
fect up to an average of 17 WT-1–positive cells per glo-
merular cross section (Figure 5). Thus, dual CCL2-
CXCL12 inhibition improves glomerular pathological
features in association with more podocytes in db/db
mice.
Figure 2. Blood glucose levels and body weight in uninephrectomized
db/db mice. Uninephrectomized db/db mice with different treatments were
monitored for blood glucose levels (A) and body weight (B) from baseline (at
the age of 16 weeks) until the end of the study (at the age of 24 weeks). Data
are given as the mean  SEM. n.s. indicates nonsignificant.
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Expression in db/db Mice
Next, we determined the mRNA expression levels of leu-
kocyte- and podocyte-related genes in kidneys of 1K
db/db mice. Both antagonists did not significantly alter
intrarenal expression of their target gene (Figure 6). How-
ever, CCL2 blockade, but not CXCL12 blockade, was
associated with lower mRNA levels of inducible nitric
oxide synthase, a parameter of activated macrophages
(Figure 6). The cytokine IL-6 showed a trend toward lower
levels in all treatment groups. In contrast, CXCL12 block-
ade increased the mRNA levels of nephrin and podocin,
two podocyte parameters, much more than CCL2 block-
ade. Dual-chemokine blockade increased these two
podocyte markers most significantly (Figure 6). Together,
CCL2 and CXCL12 single blockade has different effects
on renal mRNA expression profiles; both effects combine
Figure 3. Renal pathological features in 6-month-old db/db mice. A:
Renal sections from 1K mice of the different treatment groups were
stained with PAS. Stains show representative glomeruli from each group.
Original magnification, 400. B: PAS stains were scored from 0 to 4 for
the extent of glomerulosclerosis, as described. From each mouse, 15
glomeruli from each renal section were graded by that score. The graph
illustrates the mean  SEM percentage of each score from all mice in each
group. Uninephrectomy was associated with a shift toward higher scores
of glomerulosclerosis, as seen in the control Spiegelmer– and vehicle-
treated 1K db/db mice. Single blockade with either anti()-chemokine
Spiegelmer significantly reduced the overall scores compared with control
Spiegelmer–treated 1K db/db mice. *P  0.05. Moreover, dual blockade
further significantly reduced the percentage of glomeruli, with a score of
4, and even increased the percentage of glomeruli, with a score of 1,
compared with either single chemokine blockade. †P  0.05. n.s. indi-
cates nonsignificant.with dual blockade.Dual CCL2-CXCL12 Blockade and Glomerular
Cell Counts in db/db Mice
Glomerular pathological features are often related to an
altered cell turnover of glomerular cells. Therefore, we
determined the total numbers of glomerular cells, Ki-67
proliferating glomerular cells, and TUNEL apoptotic glo-
merular cells. Total numbers of glomerular cells were
determined by counting DAPI-positive nuclei in glomeru-
lar tuft cross sections. None of the interventions signifi-
cantly affect the total number of cell nuclei in glomerular
tufts (Figure 7A). The overall numbers of Ki-67 prolifer-
ating cells within glomeruli were low, but CCL2 and
CXCL12 blockade both significantly reduced their num-
bers in glomeruli (Figure 7B). Dual CCL2-CXCL12 block-
ade had an additive suppressive effect on glomerular cell
proliferation (Figure 7B). TUNEL apoptotic cells were
only occasionally seen and did not differ between all
treatment groups (data not shown). We conclude that
dual-chemokine blockade has an additive antiprolifera-
tive effect on glomerular cells in type 2 diabetic mice;
however, given the opposite effects (eg, on glomerular
podocyte counts), the total number of glomerular cells
was not significantly affected.
Figure 4. Glomerular leukocyte infiltrates in 1K db/db mice. A: Renal sec-
tions from 1K mice of all treatment groups were stained for CD45. Original
magnification,400. B: The graph shows the mean SEM CD45 cells in 15
glomeruli (Glom.) in sections from 6-month-old 1K db/db mice of each
group. Only anti-CCL2 Spiegelmer affected the number of glomerular CD45
†cells. *P  0.01 versus control Spiegelmer; P  0.01 versus both monothera-
pies.
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We determined the GFR by assessing fluorescein isothio-
cyanate insulin clearance kinetics in all groups of mice.
Uninephrectomy was associated with a reduced GFR
compared with a normal GFR of approximately 350 mL in
mice. Either CCL2 or CXCL12 blockade significantly in-
creased GFR in 6-month-old 1K db/db mice (Figure 8A).
Dual CCL2-CXCL12 blockade was associated with the
highest GFR (Figure 8A). Albuminuria is another clinically
important parameter of glomerular dysfunction and dam-
age. We compared urinary albumin/creatinine ratios at
the beginning and at the end of the treatment course in all
groups. CCL2 and CXCL12 significantly reduced the uri-
nary albumin/creatinine ratio when compared with control
Spiegelmer treatment at 6 months (Figure 8B). When
compared with the baseline urinary albumin/creatinine
ratio, CXCL12 and dual blockade most effectively pre-
vented proteinuria. Therefore, we conclude that dual
CCL2-CXCL12 blockade has a potent protective effect
on GFR decline. CXCL12 blockade, either alone or in
combination, effectively prevents proteinuria in 1K db/db
mice, which is consistent with its positive effect on podo-
cytes.
Figure 5. Podocyte numbers in 1K db/db mice. A: Renal sections from 1K
mice of all treatment groups were stained for WT-1. Original magnification,
400. B: The graph shows the mean  SEM WT-1–positive cells in 15
glomeruli (Glom.) in sections from 6-month-old 1K db/db mice of each
group. There was a potent effect of the anti-CXCL12 Spiegelmer on the
number of podocytes and an additive effect of dual blockade versus anti-
†CXCL12 monotherapy. *P  0.05 versus control Spiegelmer; P  0.05 versus
both monotherapies.CXCL12 Suppresses Nephrin de Novo
Expression of Podocyte Progenitors
How does CXCL12 blockade significantly increase podo-
cyte numbers and nephrin expression without any direct
effect on podocytes, which we previously excluded?15
Given the critical role of CXCL12 in the maintenance of
Figure 6. Renal mRNA expression in 1K db/db mice. RNA isolates from
kidneys of 1K db/db mice underwent quantitative real-time PCR for several
genes, as indicated. Data are expressed as mean  SEM of the ratio of the
specific mRNA versus that of 18s ribosomal RNA. *P  0.05, **P  0.01, and
***P  0.001 versus vehicle. n.s. indicates nonsignificant.
Figure 7. Proliferation of glomerular (glom.) cells in 1K db/db mice. A: The
number of DAPI cell nuclei was counted in renal sections from mice of all
groups, as indicated. B: Renal sections from mice of all groups were stained
for the proliferation marker Ki-67. The graphs show the mean SEM positive
cells in 15 glomeruli in sections from 6-month-old 1K db/db mice of each
group. *P  0.05, **P  0.01 versus control Spiegelmer treatment.
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possibility that podocyte-derived CXCL12 may regulate
the potential of renal progenitor cells to differentiate to-
ward podocytes. Several groups15–19 have recently re-
ported that a subpopulation of parietal epithelial cells in
glomeruli represents progenitor cells and has the capac-
ity to differentiate into mature podocytes by progressively
migrating and differentiating from the urinary pole of the
Bowman’s capsule toward the glomerular tuft. Therefore,
we questioned whether CXCL12 serves as a factor that
regulates the differentiation of renal progenitor cells to-
ward the podocyte phenotype. A previous report15 indi-
cated that culturing human renal progenitors in the VRAD
medium over 2 days resulted in their differentiation into
podocytes, as demonstrated by novel expression of
nephrin, WT-1, synaptopodin, podocin, and anti-glomer-
ular epithelial protein 1 at both the mRNA and protein
levels. Because CXCL12 blockade up-regulated nephrin
expression in our in vivo models, in this study, we evalu-
ated primary cultures of human renal progenitors that are
already known to express receptors for CXCL1215 for
their potential to up-regulate nephrin mRNA expression in
the presence or absence of this chemokine. The human
embryonic kidney epithelial cell line 293 and the human
keratinocyte cell line were evaluated as additional con-
trols for nephrin mRNA expression before and after treat-
ment with VRAD. As shown in Figure 9A, the effect of
VRAD treatment was irrelevant in human embryonic kid-
ney 293 and human keratinocyte cell lines, whereas it
induced strong up-regulation of nephrin mRNA expres-
sion in primary cultures of human renal progenitors, as
assessed by quantitative RT-PCR. Adding recombinant
CXCL12 suppressed nephrin mRNA up-regulation in a
dose-dependent manner (Figure 9A). When CXCL12 was
blocked with anti-CXCL12 Spiegelmer, de novo mRNA
Figure 8. GFR and albuminuria in 6-month-old db/db mice. A: GFR was
determined by fluorescein isothiocyanate–insulin clearance kinetics in all
groups at the end of the study, as described in the Materials and Methods. 1K
mice treated with dual-chemokine blockade have the GFR levels. B: Urinary
albumin/creatinine ratios (UACRs) were determined as a functional marker of
the glomerular filtration barrier at the initiation (4 months, gray bars) and
termination (6 months, black bars) of treatment. Data are given as the mean
SEM from at least six mice in each group. *P  0.05, **P  0.01 versus
control-Spiegelmer–treated 1K db/db mice; ***P 0.05 versus baseline UACR
in the respective group (gray bar).expression of nephrin was no longer compromised, aneffect that was not observed with the unspecific control
Spiegelmer (Figure 9B). Thus, CXCL12 suppresses the
potential of renal progenitors to express nephrin. Vice
versa, CXCL12 antagonism increased levels of nephrin
mRNA expression, which may explain the findings on
CXCL12 blockade in db/db mice.
Discussion
We hypothesized that dual blockade of CCL2 and
CXCL12 was superior compared with single blockade in
preventing the progression of diabetic glomerulosclero-
sis because both approaches target different disease
pathomechanisms. Our data support this hypothesis and
demonstrate that dual blockade combines the protective
effect on CCL2-mediated glomerular leukocyte recruit-
ment with that on CXCL12-mediated loss of podocytes.
Thus, our data render dual CCL2-CXCL12 blockade as a
novel strategy to more efficiently prevent glomeruloscle-
rosis in type 2 diabetes.
Data of the present study confirm previous reports13,15
on CCL2 blockade with Spiegelmers in the same exper-
imental setup. Attempts to increase the therapeutic ben-
efit by initiating treatment earlier were not successful.19 In
contrast, even a later onset of anti-CCL2 Spiegelmer
treatment (from the age of 5 months) was equally effec-
tive in preventing glomerulosclerosis in 1K db/db mice.19
In the present and in previous studies, CCL2 blockade
Figure 9. CXCL12 and de novo nephrin expression in renal progenitor cells.
A: Human embryonic kidney 293 cells, human keratinocyte cells (HACAT),
and human renal progenitors were cultured in VRAD medium, as described
in the Materials and Methods. Data are expressed as fold increase versus the
respective untreated cell type, as assessed in an identical number of cells. On
human renal progenitors, recombinant CXCL12 was added at different con-
centrations, as indicated, and nephrin mRNA expression was determined by
real-time RT-PCR. B: Cells were cultured as before, plus adding anti-CXCL12
or control Spiegelmer. Only anti-CXCL12 Spiegelmer prevented the CXCL12-
mediated suppression of de novo nephrin mRNA expression. Data are ex-
pressed as fold increase versus VRAD-treated renal progenitors (B), as as-
sessed in an identical number of cells. Data are given as mean  SEM. *P 
0.05.
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AJP July 2011, Vol. 179, No. 1resulted in a 50% to 60% reduction of glomerular leuko-
cytes that entirely represent macrophages in the db/db
mouse model.21 These findings are consistent with data
from models of types 1 and 2 diabetes in Ccl2-deficient
mice11,12 or with CCR2 blockade in 1K db/db mice.22
CCR2 macrophages belong to the proinflammatory
(M1) phenotype that contributes to intrarenal inflamma-
tion and tissue damage via the release of reactive oxygen
species or cytokines, such as tumor necrosis factor-
.23,24 Thus, anti–CCL2-Spiegelmer–treated 1K db/db
mice revealed fewer glomerular leukocytes that were as-
sociated with lower intrarenal mRNA levels of inducible
nitric oxide synthase, IL-6, or tumor necrosis factor- at
the end of the study. Consistent with previous findings,
the protection from glomerulosclerosis with CCL2 block-
ade correlated with some lower levels of proteinuria and
a higher GFR. Thus, CCL2 blockade prevents the pro-
gression of DN by interfering with macrophage-driven
glomerular inflammation.
The present study also reconfirms previous data15 on
CXCL12 blockade in this model. NOX-A12 prevented the
progression of glomerulosclerosis in 1K db/db mice with-
out affecting glomerular leukocyte counts, indicating that
the homeostatic chemokine CXCL12 is not involved in
glomerular leukocyte recruitment. Recently, CXCL12 was
constitutively expressed in podocytes.15 CXCL12 block-
ade also increased podocyte numbers in 1K db/db mice
in the present study. Furthermore, CXCL12 blockade in-
creased renal mRNA expression levels of nephrin and
podocin, two podocyte-slit membrane-related proteins
that serve as markers of podocyte differentiation.25 Podo-
cyte damage is an important pathomechanism promoting
the progression of diabetic glomerulosclerosis and
seems to result from various triggers that foster podocyte
dedifferentiation and podocyte apoptosis.26 It remains
unclear whether the beneficial effect of CXCL12 block-
ade on podocyte numbers relates to a protective effect
on podocyte death or detachment or is the result of
enhanced podocyte regeneration from local podocyte
progenitors (eg, from parietal epithelial cells).27,28 The
latter concept may be more likely because CXCL12
blockade also mobilizes hematopoietic progenitor cells
from the bone marrow.29–31 In fact, our in vitro studies
demonstrate that CXCL12 suppressed the induced mat-
uration of renal progenitors toward podocytes, as docu-
mented by inhibition of de novo nephrin expression. This
effect was specific to renal progenitors and was not ob-
served in other epithelial cells. Our in vitro finding that
CXCL12 blockade reverts this inhibitory effect on nephrin
expression may correspond to our in vivo observation that
CXCL12 blockade increased renal nephrin mRNA ex-
pression and podocyte numbers. Thus, CXCL12 block-
ade may enhance renal progenitor differentiation toward
the podocyte lineage, thus enhancing podocyte regen-
eration.
Thus, one hypothesis is that dual blockade with anti–
CCL2- and anti–CXCL12-Spiegelmers could lead to
Spiegelmer-Spiegelmer interaction effects, such as com-
plex formation or additive off-target effects. However, the
plasma chemokine level analysis confirmed that dual
blockade does not significantly affect the biological ac-tivity of each Spiegelmer in terms of binding its natural
target (in the plasma). This observation is consistent with
the finding that 1K db/db mice with dual blockade reca-
pitulate the biological effects of single blockade. For ex-
ample, 1K db/db mice treated with dual blockade dis-
played the reduction of glomerular leukocytes and a
trend toward lower inducible nitric oxide synthase and
tumor necrosis factor- expression to the same extent as
seen with CCL2 blockade. In addition, dual blockade
also increased podocyte numbers and nephrin or podo-
cin mRNA expression to the same extent as seen with
CXCL12 blockade only. As a result, the combination of
these different ways dual blockade was more potent than
single blockade in preventing diffuse glomerulosclerosis
was evidenced by significantly fewer glomeruli with
global glomerulosclerosis and significantly more normal
glomeruli. This additive therapeutic effect was less prom-
inent for GFR and proteinuria because CXCL12 blockade
by itself already had a profound effect on these two
functional end points. Together, these data first docu-
ment that chemokine antagonist combinations hold a po-
tential for additive preventive effects on (diabetic) glo-
merulosclerosis when the individual chemokine targets
mediate different pathomechanisms in the specific dis-
ease process (ie, inflammation and renal progenitor dif-
ferentiation toward the podocyte lineage).
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